ABT · 10-Q · 2026Q3 · Full report

Operating Income and Margins

ABBOTT LABORATORIES · 2026-11-04 · Importance 58 · Surprise 56

Third-quarter operating earnings fell 34% to $1.358 billion from $2.057 billion, while nine-month operating earnings declined 24% to $4.396 billion from $5.802 billion. Third-quarter net sales grew 14% to $13.013 billion, so operating earnings declined despite higher sales. Nine-month cost of products sold, excluding intangible amortization, increased to $15.843 billion from $14.397 billion, while total operating costs and expenses rose to $32.374 billion from $27.067 billion. The filing reports $1.921 billion of nine-month intangible amortization in 2026, compared with $1.260 billion in 2025, and estimates approximately $3.0 billion of amortization expense for full-year 2026.